Related Experiment Video
Updated: Aug 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
What works in medication reconciliation: an on-treatment and site analysis of the MARQUIS2 study
Jeffrey L Schnipper1,2,3, Harry Reyes Nieva4,2, Catherine Yoon4
1Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital Department of Medicine, Boston, Massachusetts, USA jschnipper@bwh.harvard.edu.
Background:
The second Multicenter Medication Reconciliation Quality Improvement Study demonstrated a marked reduction in medication discrepancies per patient. The aim of the current analysis was to determine the association of patient exposure to each system-level intervention and receipt of each patient-level intervention on these results.
Methods:
This study was conducted at 17 North American Hospitals, the study period was 18 months per site, and sites typically adopted interventions after 2-5 months of preintervention data collection. We conducted an on-treatment analysis (ie, an evaluation of outcomes based on patient exposure) of system-level interventions, both at the category level and at the individual component level, based on monthly surveys of implementation site leads at each site (response rate 65%). We then conducted a similar analysis of patient-level interventions, as determined by study pharmacist review of documented activities in the medical record. We analysed the association of each intervention on the adjusted number of medication discrepancies per patient in admission and discharge orders, based on a random sample of up to 22 patients per month per site, using mixed-effects Poisson regression with hospital site as a random effect. We then used a generalised linear mixed-effects model (GLMM) decision tree to determine which patient-level interventions explained the most variance in discrepancy rates.
Results:
Among 4947 patients, patient exposure to seven of the eight system-level component categories was associated with modest but significant reductions in discrepancy rates (adjusted rate ratios (ARR) 0.75-0.97), as were 15 of the 17 individual system-level intervention components, including hiring, reallocating and training personnel to take a best possible medication history (BPMH) and training personnel to perform discharge medication reconciliation and patient counselling. Receipt of five of seven patient-level interventions was independently associated with large reductions in discrepancy rates, including receipt of a BPMH in the emergency department (ED) by a trained clinician (ARR 0.40, 95% CI 0.37 to 0.43), admission medication reconciliation by a trained clinician (ARR 0.57, 95% CI 0.50 to 0.64) and discharge medication reconciliation by a trained clinician (ARR 0.64, 95% CI 0.57 to 0.73). In GLMM decision tree analyses, patients who received both a BPMH in the ED and discharge medication reconciliation by a trained clinician experienced the lowest discrepancy rates (0.08 per medication per patient).
Conclusion And Relevance:
Patient-level interventions most associated with reductions in discrepancies were receipt of a BPMH of admitted patients in the ED and admission and discharge medication reconciliation by a trained clinician. System-level interventions were associated with modest reduction in discrepancies for the average patient but are likely important to support patient-level interventions and may reach more patients. These findings can be used to help hospitals and health systems prioritise interventions to improve medication safety during care transitions.
Insights
Patient-level interventions, like obtaining a best possible medication history in the ED and clinician-led reconciliation, significantly reduce medication discrepancies. System-level changes support these efforts for improved patient safety during care transitions.
Area of Science:
- Health Services Research
- Patient Safety
- Medication Management
Background:
- The second Multicenter Medication Reconciliation Quality Improvement Study showed reduced medication discrepancies.
- This analysis investigates the impact of system-level and patient-level interventions on these outcomes.
Purpose of the Study:
- To determine the association between patient exposure to system-level interventions and receipt of patient-level interventions with reduced medication discrepancies.
- To identify which interventions are most effective in decreasing medication errors.
Main Methods:
- An on-treatment analysis of system-level interventions using monthly surveys.
- Analysis of patient-level interventions via pharmacist review of medical records.
- Mixed-effects Poisson regression and GLMM decision trees were used to analyze associations.
Main Results:
- Seven of eight system-level intervention categories and 15 individual components showed modest reductions in discrepancies.
- Five of seven patient-level interventions significantly reduced discrepancies, notably a best possible medication history (BPMH) in the ED and clinician-led admission/discharge reconciliation.
- Patients receiving both an ED BPMH and discharge reconciliation had the lowest discrepancy rates.
Conclusions:
- Patient-level interventions, particularly obtaining a BPMH in the ED and clinician-led reconciliation, are most effective in reducing medication discrepancies.
- System-level interventions play a supportive role and increase reach.
- Findings guide prioritization of interventions to enhance medication safety during care transitions.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Metabolism: Phase II Reactions
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Acute Coronary Syndrome III: Diagnostic Studies

